Black Diamond Therapeutics, (BDTX) announced that Chairman of the Board of Directors, Robert Ingram, has stepped down due to personal reasons. Existing Board member, Mark Velleca, M.D., Ph.D., has been appointed to succeed Ingram as the next Chairman. Dr. Mark Velleca has been a member of our Board since August 2021. Dr Velleca is currently the CEO of StrideBio, a gene therapy company. Previously, Mark served as CEO of G1 Therapeutics (GTHX) until 2021y.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BDTX:
- Black Diamond Therapeutics Announces Changes to Board of Directors
- Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
- Black Diamond Therapeutics announces spinout of Launchpad Therapeutics
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
- Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
